SBIR Phase I: Nanoparticle Antimicrobial Coatings on Natural Scaffolds for Tissue Reconstruction

SBIR 第一阶段：天然支架上的纳米粒子抗菌涂层用于组织重建

• 批准号: 1046687
• 负责人: Aaron Strickland
• 金额: $ 15万
• 依托单位: iFyber, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1046687&HistoricalAwards=false
• 关键词: SBIR; Phase; Nanoparticle; Antimicrobial; Coatings

This Small Business Innovation Research Phase I project addresses the important problem of combating hospital acquired infections with the development of novel tissue matrices aimed at preventing nosocomial microbial infection. The aim of this project is to combine antimicrobial nanomaterials and a natural dermis product to help prevent infections that occur during reconstructive surgeries. This proof-of-concept study will develop methods for the production of uniform and conformal coatings on natural tissue matrices using layer-by-layer assembly of antimicrobial nanoparticles. Importantly, this project will evaluate the efficacy of nanocoated natural dermis in eliminating or inhibiting bacterial growth in liquid and solid media. In vitro studies also will be conducted to establish mammalian cell toxicity and viability of the engineered dermis in supporting mammalian cell growth. Phase I results are expected to produce an optimized antimicrobial dermis scaffold that will be carried onto a focused Phase II evaluation in animal experimental wounds.The broader impact/commercial potential of this project will address the growing problem of hospital acquired infections from antibiotic resistant pathogens. With nearly 1.7 million hospital-acquired infections and 99,000 deaths per year, increases in antibiotic-resistant bacterial strains represent a critical safety concern and a significant cost burden to our nation's health care system. The proposed technology is a versatile option that provides a broad spectrum solution in combating bacterial infections and the prevalence of antibiotic resistance. Furthermore, the methods used to characterize the proposed composite materials will add valuable insight into mechanisms associated with nanoparticle-derived antimicrobial activity, and will help guide future efforts in the arena of nanobiotechnology.

这个小企业创新研究第一阶段项目解决了通过开发旨在预防医院微生物感染的新型组织基质来对抗医院获得性感染的重要问题。 该项目的目的是将联合收割机抗菌纳米材料和天然真皮产品结合起来，以帮助预防重建手术期间发生的感染。 这项概念验证研究将开发使用抗菌纳米颗粒的逐层组装在天然组织基质上生产均匀和保形涂层的方法。 重要的是，该项目将评估纳米涂层天然真皮在消除或抑制液体和固体培养基中细菌生长的功效。 还将进行体外研究，以确定支持哺乳动物细胞生长的工程真皮的哺乳动物细胞毒性和活力。 第一阶段的结果预计将产生一个优化的抗菌真皮支架，将进行一个集中的第二阶段评估在动物实验wounds.The更广泛的影响/商业潜力，该项目将解决日益严重的问题，医院获得性感染的抗生素耐药病原体。 每年有近170万例医院获得性感染和99，000例死亡，抗药性细菌菌株的增加是一个严重的安全问题，也是我国医疗保健系统的重大成本负担。 拟议的技术是一种多功能的选择，为对抗细菌感染和抗生素耐药性的流行提供了一种广谱的解决方案。 此外，用于表征所提出的复合材料的方法将增加与纳米颗粒衍生的抗微生物活性相关的机制的有价值的见解，并将有助于指导未来的努力在纳米生物技术的竞技场。